Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance Annual Conference
PIRSDelisted Stock | USD 13.60 1.41 9.39% |
Slightly above 61% of Pieris Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Pieris Pharmaceuticals suggests that many traders are alarmed regarding Pieris Pharmaceuticals' prospects. Pieris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Pieris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Pieris |
Poster presentations include data supporting QTORIN rapamycin 3.9 percent anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA studyWAYNE, PA., Oct. 15, 2024 -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies
Read at finance.yahoo.com
Pieris Pharmaceuticals Fundamental Analysis
We analyze Pieris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pieris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pieris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Pieris Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Pieris Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pieris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Pieris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pieris Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Pieris Pharmaceuticals Related Equities
CUE | Cue Biopharma | 25.90 | ||||
ADAP | Adaptimmune Therapeutics | 4.84 | ||||
CRVS | Corvus Pharmaceuticals | 3.43 | ||||
ACHL | Achilles Therapeutics | 1.75 | ||||
AGEN | Agenus | 1.22 | ||||
MREO | Mereo BioPharma | 0.80 | ||||
AFMD | Affimed NV | 0.74 | ||||
LPTX | Leap Therapeutics | 0.30 | ||||
CKPT | Checkpoint Therapeutics | 0.27 | ||||
TERN | Terns Pharmaceuticals | 0.70 | ||||
XFOR | X4 Pharmaceuticals | 1.33 | ||||
ADCT | ADC Therapeutics | 3.96 | ||||
PDSB | PDS Biotechnology | 5.00 | ||||
INZY | Inozyme Pharma | 5.86 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Pieris Stock
If you are still planning to invest in Pieris Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pieris Pharmaceuticals' history and understand the potential risks before investing.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |